MX2019012950A - Metodos de tratamiento mediante el uso de un compuesto inhibidor de jak. - Google Patents

Metodos de tratamiento mediante el uso de un compuesto inhibidor de jak.

Info

Publication number
MX2019012950A
MX2019012950A MX2019012950A MX2019012950A MX2019012950A MX 2019012950 A MX2019012950 A MX 2019012950A MX 2019012950 A MX2019012950 A MX 2019012950A MX 2019012950 A MX2019012950 A MX 2019012950A MX 2019012950 A MX2019012950 A MX 2019012950A
Authority
MX
Mexico
Prior art keywords
methods
treatment
inhibitor compound
jak inhibitor
compound
Prior art date
Application number
MX2019012950A
Other languages
English (en)
Inventor
Zhang Hao
R Thalladi Venkat
A Kleinschek Melanie
D Crater Glenn
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019012950A publication Critical patent/MX2019012950A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se relaciona con métodos para tratar enfermedades oculares y determinadas enfermedades respiratorias mediante el uso del compuesto 5-etil-2-fluoro-4-(3-(5-(1-metilpiperidin-4-il)- 4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-il)-1H-indazol-6-il )fenol (ver fórmula) o una sal farmacéuticamente aceptable del mismo.
MX2019012950A 2017-05-01 2018-04-30 Metodos de tratamiento mediante el uso de un compuesto inhibidor de jak. MX2019012950A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492568P 2017-05-01 2017-05-01
PCT/US2018/030140 WO2018204233A1 (en) 2017-05-01 2018-04-30 Methods of treatment using a jak inhibitor compound

Publications (1)

Publication Number Publication Date
MX2019012950A true MX2019012950A (es) 2019-12-16

Family

ID=62165728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012950A MX2019012950A (es) 2017-05-01 2018-04-30 Metodos de tratamiento mediante el uso de un compuesto inhibidor de jak.

Country Status (16)

Country Link
US (4) US10406148B2 (es)
EP (1) EP3609498A1 (es)
JP (2) JP7153031B2 (es)
KR (1) KR102568333B1 (es)
CN (1) CN110573157B (es)
AU (1) AU2018261588A1 (es)
BR (1) BR112019022665A2 (es)
CA (1) CA3059785A1 (es)
CL (1) CL2019003126A1 (es)
MX (1) MX2019012950A (es)
PH (1) PH12019502345A1 (es)
RU (1) RU2764979C2 (es)
SG (1) SG11201909019SA (es)
TW (1) TW201900170A (es)
WO (1) WO2018204233A1 (es)
ZA (1) ZA201906817B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
TWI808250B (zh) 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
KR20210056381A (ko) 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
JP2022506111A (ja) 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
EP3982928A4 (en) * 2019-06-17 2023-07-19 Biomarck Pharmaceuticals, Ltd. PEPTIDES AND METHODS FOR THEIR USE IN THE TREATMENT OF UVEITIS
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN111973599A (zh) * 2020-08-07 2020-11-24 杭州邦顺制药有限公司 用于眼部疾病治疗的化合物
TW202304902A (zh) * 2021-03-26 2023-02-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之二鹽酸鹽之結晶形式

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
EP2089369B1 (en) 2006-10-19 2011-02-02 Rigel Pharmaceuticals, Inc. 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP5512665B2 (ja) 2008-06-20 2014-06-04 ジェネンテック， インコーポレイテッド トリアゾロピリジンｊａｋ阻害剤化合物と方法
WO2010039825A2 (en) * 2008-10-01 2010-04-08 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
EP2459195A1 (en) 2009-07-28 2012-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
PL3001903T3 (pl) 2009-12-21 2018-03-30 Samumed, Llc 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EA024026B1 (ru) 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2015061665A1 (en) * 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
EP3318565B1 (en) 2013-12-05 2021-04-14 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
EP3943500A1 (en) 2014-04-30 2022-01-26 Agilent Technologies, Inc. Phosphorous protecting groups and methods of preparation and use thereof
TN2016000503A1 (en) 2014-05-14 2018-04-04 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
WO2017077288A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
CA3037243A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1 h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
KR20180073687A (ko) * 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound

Also Published As

Publication number Publication date
EP3609498A1 (en) 2020-02-19
BR112019022665A2 (pt) 2020-05-19
JP7153031B2 (ja) 2022-10-13
US10548886B2 (en) 2020-02-04
NZ758109A (en) 2021-09-24
US11160800B2 (en) 2021-11-02
US20190350916A1 (en) 2019-11-21
JP2020518579A (ja) 2020-06-25
SG11201909019SA (en) 2019-10-30
PH12019502345A1 (en) 2020-12-07
CL2019003126A1 (es) 2020-01-24
TW201900170A (zh) 2019-01-01
US10406148B2 (en) 2019-09-10
RU2764979C2 (ru) 2022-01-24
CN110573157A (zh) 2019-12-13
US20220008403A1 (en) 2022-01-13
KR102568333B1 (ko) 2023-08-18
WO2018204233A1 (en) 2018-11-08
US11786517B2 (en) 2023-10-17
RU2019138463A (ru) 2021-06-02
CN110573157B (zh) 2023-04-04
JP2022120147A (ja) 2022-08-17
ZA201906817B (en) 2021-10-27
US20200121669A1 (en) 2020-04-23
RU2019138463A3 (es) 2021-08-03
CA3059785A1 (en) 2018-11-08
AU2018261588A1 (en) 2019-10-31
US20180311226A1 (en) 2018-11-01
KR20190140062A (ko) 2019-12-18

Similar Documents

Publication Publication Date Title
MX2019012950A (es) Metodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
MX2021008342A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12015502549A1 (en) Heterocyclic derivatives
SG10201907819WA (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
PH12019502425A1 (en) Crystalline forms of a jak inhibitor compound
EA201990833A1 (ru) Соединение пиридина
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
ZA201904522B (en) Heterocyclic inhibitors of mct4
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
PL428024A1 (pl) Sulfonowana pochodna polistyrenu do zastosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez kociego herpeswirusa
MX2023002539A (es) Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).